Latest news

• NICE backs use of anti-cholesterol drug Ezetrol

  Draft guidance reflects 'greater emphasis on managing CVD risk'. NICE has recommended Merck Sharp &Dohme's cholesterol drug Ezetrol (ezetimibe) in draft guidance. ... In this way Ezetrol can be combined with statins to provide a complementary or

• FDA approves four new medicines across multiple areas

  Sanofi/Regeneron, BMS, AbbVie and Novartis all chalk up major approvals. The FDA has given the green light to four major new treatments for skin cancer, patients with high cholesterol and ... First up, Sanofi and Regeneron's eagerly anticipated injected

• Sanofi and Regeneron pay $67.5m to speed alirocumab review

  Buy FDA priority review voucher from BioMarin. Sanofi and Regeneron Pharmaceuticals are paying $67.5m for an unusual licence which could enable them to get anti-cholesterol product alirocumab onto the

• Amgen profits down on rising costs

  Broadway pointed to the start of phase III trials for four new projects in 2012, namely anti-cholesterol antibody AMG-145, romosuzamab for osteoporosis, brodalumab for psoriasis and rilotumamab for gastric

• Philippines forces drug price cuts

  The mandatory 50 per cent price cuts will cover the anti-hypertensive amlodipine, the antibiotic azithromycin, cholesterol-lowering atorvastatin and two cancer treatments – doxorubicin and cytarabine.